The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: A pilot investigation

Anesthesia and Analgesia

Volumn 95, Issue 1, 2002, Pages 26-30

  Koster, Andreas ^a   Despotis, George ^a   Gruendel, Marcus ^a   Fischer, Thomas ^a   Praus, Michael ^a   Kuppe, Herman ^a   Levy, Jerrold H ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; INFUSORIAL EARTH; KAOLIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; FEMALE; HEMODILUTION; HEMOSTASIS; HEPARINIZATION; HUMAN; MALE; PATIENT MONITORING; PLASMA; PRIORITY JOURNAL;

EID: 0036297734     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200207000-00004     Document Type: Article

References (16)

1. Anticoagulation monitoring during cardiac surgery
2. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update
3. More effective suppression of hemostatic system activation in patients undergoing surgery by heparin dosing based on heparin blood concentrations rather than ACT
4. The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac surgery
5. Maintenance of blood heparin concentration, rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass
6. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques
7. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery
8. Reliability of the heparin management test for monitoring high levels of unfractionated heparins: In vitro findings in volunteers versus in vivo findings during cardiopulmonary bypass
9. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentrations in patients having cardiac operations
10. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements
11. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X
12. A quick anti-Xa-activitybased whole blood coagulation assay for monitoring unfractionated heparin cardiopulmonary bypass: A pilot investigation
13. Hirudin determination in plasma can be strongly influenced by the prothrombin level
14. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: Adaptation of the ecarin clotting time to the act II device
15. The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery
16. An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation